Smith & Nephew (SNN) Cash from Investing Activities (2009 - 2024)
Smith & Nephew (SNN) posted quarterly Cash from Investing Activities of -$360.0 million for Q4 2024, down 97.8% year-on-year from -$16.4 billion in Q1 2024, and down 97.8% on a QoQ basis from -$182.0 million in Q4 2023.
Smith & Nephew (SNN) Cash from Investing Activities (2009 - 2024) Analysis & Trends
Smith & Nephew (SNN) has reported Cash from Investing Activities for 16 consecutive years, with -$360.0 million the latest figure, recorded in Q4 2024.
- Quarterly Cash from Investing Activities fell 97.8% year-over-year to -$360.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$1.2 billion (down 2.82% YoY) and the FY2025 annual result came in at -$406.0 million, up 28.65% from the prior year.
- Cash from Investing Activities declined to -$360.0 million in Q4 2024 per SNN's latest filing, from -$182.0 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for SNN reached as high as -$182.0 million in Q4 2023 and fell as low as -$431.0 million in Q4 2021.
- A 5-year average of -$313.4 million and a median of -$326.0 million in 2020 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2020 — Cash from Investing Activities soared 73.94% — and 2024, when it plunged 97.8%.
- Year by year, Cash from Investing Activities stood at -$326.0 million in 2020, then slumped by 32.21% to -$431.0 million in 2021, then surged by 37.82% to -$268.0 million in 2022, then jumped by 32.09% to -$182.0 million in 2023, then tumbled by 97.8% to -$360.0 million in 2024.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$360.0 million, -$182.0 million, and -$268.0 million for Q4 2024, Q4 2023, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -20.32 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | -185.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -591.00 Mn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -92.80 Mn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -298.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -2.50 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -475.32 Mn |
| 10 | Steris | 21.47 Bn | 21.03 Bn | 697.10 Mn | -217.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -360.00 Mn |
| Dec 31, 2024 | -360.00 Mn |
| Dec 31, 2023 | -182.00 Mn |
| Dec 31, 2023 | -182.00 Mn |
| Dec 31, 2022 | -268.00 Mn |
| Dec 31, 2022 | -268.00 Mn |
| Dec 31, 2021 | -431.00 Mn |
| Dec 31, 2021 | -431.00 Mn |
| Dec 31, 2020 | -326.00 Mn |
| Dec 31, 2020 | -326.00 Mn |
| Dec 31, 2019 | -1.25 Bn |
| Dec 31, 2019 | -1.25 Bn |
| Dec 31, 2018 | -378.00 Mn |
| Dec 31, 2018 | -378.00 Mn |
| Dec 31, 2017 | -543.00 Mn |
| Dec 31, 2017 | -543.00 Mn |
| Dec 31, 2016 | -388.00 Mn |
| Dec 31, 2016 | -388.00 Mn |
| Dec 31, 2015 | -429.00 Mn |
| Dec 31, 2015 | -429.00 Mn |